CoChat

Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial

Open access

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Abstract

Rationale: Less invasive, nonsurgical approaches are needed to treat severe emphysema. Objectives: To evaluate the effectiveness and safety of the Spiration Valve System (SVS) versus optimal medical management. Methods: In this multicenter, open-label, randomized, controlled trial, subjects aged 40 years or older with severe, heterogeneous emphysema were randomized 2:1 to SVS with medical management (treatment) or medical management alone (control). Measurements and Main Results: The primary efficacy outcome was the difference in mean FEV1 from baseline to 6 months. Secondary effectiveness outcomes included: difference in FEV1 responder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise capacity. The primary safety outcome was the incidence of composite thoracic serious adverse events. All analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference between treatment and control arms. Between October 2013 and May 2017, 172 participants (53.5% male; mean age, 67.4 yr) were randomized to treatment (n = 113) or control (n = 59). Mean FEV1 showed statistically significant improvements between the treatment and control groups—between-group difference at 6 and 12 months, respectively, of 0.101 L (95% BCI, 0.060–0.141) and 0.099 L (95% BCI, 0.048–0.151). At 6 months, the treatment group had statistically significant improvements in all secondary endpoints except 6-minute-walk distance. Composite thoracic serious adverse event incidence through 6 months was greater in the treatment group (31.0% vs. 11.9%), primarily due to a 12.4% incidence of serious pneumothorax. Conclusions: In patients with severe heterogeneous emphysema, the SVS shows significant improvement in multiple efficacy outcomes, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT01812447).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201902-0383oc

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Key components of the Spiration Valve.
Figure 1. Key components of the Spiration Valve.CC BY-NC-ND · PubMed Central
Figure 2. Study subject disposition flow chart.
Figure 2. Study subject disposition flow chart.CC BY-NC-ND · PubMed Central
Figure 3. Change in FEV1 at 6 and 12 months; data are shown as mean and 95% Bayesian credible interval (BCI). PP = posterior probability; SVS = Spiration Valve System.
Figure 3. Change in FEV1 at 6 and 12 months; data are shown as mean and 95% Bayesian credible interval (BCI). PP = posterior probability; SVS = Spiration Valve System.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 3

  1. Elstad, 2012, Bronchial valve treatment of emphysema: procedure and device safety results from a double-blind randomized trial [abstract], Am J Respir Crit Care Med, 185, A1112
  2. Criner, 2018, The EMPROVE trial: a randomized, controlled multicenter clinical study to evaluate the safety and effectiveness of the Spiration® Valve System for single lobe treatment of severe emphysema [abstract], Am J Respir Crit Care Med, 197, A7753
  3. Criner, 2018, Endobronchial valves for severe emphysema: 12-month results of the EMPROVE trial, Eur Respir J, 52, OA4928

Cited by

See all 182

Metadata

Authors
Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., Wellikoff, A., Calero, K., Rumbak, M. J., Branca, P. R., Abu-Hijleh, M., Mallea, J. M., Kalhan, R., Sachdeva, A., Kinsey, C. M., Lamb, C. R., Reed, M. F., Abouzgheib, W. B., Kaplan, P. V., Marrujo, G. X., Johnstone, D. W., Gasparri, M. G., Meade, A. A., Hergott, C. A., Reddy, C., Mularski, R. A., Case, A. H., Makani, S. S., Shepherd, R. W., Chen, B., Holt, G. E., & Martel, S.
Affiliations
  • Temple University (US)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Sarasota Memorial Hospital (US)
  • University of Chicago Medical Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • Carolinas Medical Center (US)
  • Michael E. DeBakey VA Medical Center (US)
  • University of Cincinnati (US)
  • Louisiana State University Health Sciences Center Shreveport (US)
  • University of South Florida (US)
  • University of Tennessee Medical Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • Mayo Clinic in Florida (US)
  • Northwestern University (US)
  • University of Maryland Medical Center (US)
  • University of Vermont Medical Center (US)
  • Lahey Hospital and Medical Center (US)
  • Penn State Milton S. Hershey Medical Center (US)
  • Cooper University Hospital (US)
  • Botsford Hospital (US)
  • Kaiser Permanente Riverside Medical Center (US)
  • Froedtert Hospital (US)
  • Sparks Regional Medical Center, Fort Smith, Arkansas
  • University of Calgary (CA)
  • University of Utah (US)
  • Kaiser Permanente (US)
  • Piedmont Atlanta Hospital (US)
  • University of California San Diego (US)
  • Virginia Commonwealth University (US)
  • California Pacific Medical Center (US)
  • Miami VA Healthcare System (US)
Corresponding author
Criner, Gerard J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2019-12-01
Volume
200
Issue
11
Pages
1354-1362
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2964927788
Cited by
182
References
35
Citations by year
2026: 20 · 2025: 29 · 2024: 30 · 2023: 24 · 2022: 20 · 2021: 28 · 2020: 26 · 2019: 5
FWCI
14.50
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Spiration Inc. d.b.a. Olympus Respiratory America
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
heterogeneous emphysema, lung volume reduction, FEV1, lung function, pneumothorax, hyperinflation, dyspnea, exercise capacity, conservative treatment, chronic obstructive pulmonary disease
MeSH terms
Aged, Inhalation, Bronchi, Female, Forced Expiratory Volume, Humans, Lung, Male, Pulmonary Emphysema, Treatment Outcome, Prostheses and Implants

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.201902-0383oc
The paper
Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., Wellikoff, A., Calero, K., Rumbak, M. J., Branca, P. R., Abu-Hijleh, M., Mallea, J. M., Kalhan, R., Sachdeva, A., Kinsey, C. M., . . . Martel, S. (2019). Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201902-0383oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.